Current location:


Choose your location:

Turkish Ambassador to China Visits SINOVAC in Beijing


Ambassador Musa and SINOVAC Chairman Explore Continued Investment and Cooperation


On November 8, Dr. Ismail Hak Musa, Turkish Ambassador to China, visited Sinovac Biotech Ltd. ("SINOVAC" or the "Company") in Beijing to meet with Mr. Weidong Yin, Chairman, President, and CEO of SINOVAC. The two parties explored opportunities for SINOVAC's further investment and collaboration in Türkiye following the recent inauguration of KeyVac, a SINOVAC joint venture in Ankara that significantly boosts local vaccine production capacity.


MetInfo enterprise content manager system | MetInfo CMS

MetInfo enterprise content manager system | MetInfo CMS

Ambassador Musa advocated for continued SINOVAC investments, while Mr. Yin underscored how the Company's commitment to expanding its presence and operations, as well as expressed his expectation on gaining more support from the Turkish government.


During his visit, Ambassador Musa toured SINOVAC's state-of-the-art COVID-19 vaccine production area with Ms. Helen Yang, Chief Business Officer of SINOVAC, for additional insights into the Company's vaccine development and production.


The meeting focused on SINOVAC's deepening engagement with the Turkish government, following President Recep Tayyip Erdoğan's attendance at the inauguration ceremony of KeyVac's vaccine production center, on October 31. There, the president emphasized the strategic importance of local vaccine production after the COVID-19 pandemic. With KeyVac's added capabilities, Türkiye can produce the hepatitis A vaccine to high standards domestically he said, adding that the plant benefits not only the city of Ankara, but all of Türkiye and its people.


KeyVac, firstly broke ground in November 2021, a vaccine company with the production capacity of 30 million doses per year. Leveraging SINOVAC's cutting-edge technology, KeyVac will develop, produce, and supply vaccines that meet Türkiye's local immunization plan, beginning with the hepatitis A vaccine. KeyVac obtained Good Manufacturing Practice (GMP) certification for producing hepatitis A vaccines in October 2023.


SINOVAC has long served as a key ally in Türkiye's national healthcare efforts, supplying the country with millions of doses of its vaccines and supporting local communities in the fight against infectious diseases, such as varicella and COVID-19. During the pandemic, SINOVAC's joint research with Turkish scientists on the COVID-19 inactivated vaccine was published in the world-leading academic journal The Lancet and played an important role providing crucial scientific evidence for the vaccine’s global deployment. This scientific partnership has fostered innovation and earned trust for SINOVAC’s mission to supply vaccines to eliminate human diseases.




Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to pipeline development including but not limited to new technology, new vaccines as well as other biomedical products. We will constantly explore global opportunities of strategic expansion.


For more information, please visit the Company’s website at



Sinovac Biotech Ltd. 

PR Team